{
    "organizations": [],
    "uuid": "098768462cd73f46e98911fe42cab3c1adc31a7f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-health-canada-approves-roches-ocre/brief-health-canada-approves-roches-ocrevus-for-type-of-multiple-sclerosis-idUSFWN1Q510T",
    "ord_in_thread": 0,
    "title": "BRIEF-Health Canada Approves Roche's Ocrevus For Type of Multiple Sclerosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 15, 2018 / 1:18 PM / Updated 6 minutes ago BRIEF-Health Canada Approves Roche's Ocrevus For Type of Multiple Sclerosis Reuters Staff Feb 15 (Reuters) - Roche Holding Ag: * HEALTH CANADA APPROVES OCREVUS® (OCRELIZUMAB) FOR CANADIANS LIVING WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) * ‍ROCHE CANADA- HEALTH CANADA HAS APPROVED OCREVUS UNDER PROVISIONS MADE WITHIN ITS NOTICE OF COMPLIANCE WITH CONDITIONS POLICY​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-15T15:17:00.000+02:00",
    "crawled": "2018-02-15T15:43:03.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "canada",
        "approves",
        "roche",
        "ocrevus",
        "type",
        "multiple",
        "sclerosis",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "roche",
        "holding",
        "ag",
        "health",
        "canada",
        "approves",
        "ocrelizumab",
        "canadian",
        "living",
        "primary",
        "progressive",
        "multiple",
        "sclerosis",
        "ppms",
        "health",
        "canada",
        "approved",
        "ocrevus",
        "provision",
        "made",
        "within",
        "notice",
        "compliance",
        "condition",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}